RECURRENT GLIOMA

This study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…

This early-stage trial tests a new immune cell therapy for people with recurrent or treatment-resistant malignant glioma, a type of brain cancer. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells. The main goals are to …

This study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …

This study tests a new type of MRI scan that looks at sodium and other signals in the brain to better understand tumors. It includes healthy volunteers and people with brain tumors (glioma). The goal is to improve how doctors detect and monitor these tumors, which could lead to b…

This early-phase trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation. The main goal is to measure how much drug gets into the tumor and how it affects cancer cell activity, not t…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…

This study was designed to see if a diet low in two nutrients (cysteine and methionine) could change how the body and brain tumor cells work in people with recurrent glioma. Up to 30 participants would have been randomly assigned to either a regular diet or the special diet for 2…